Literature DB >> 22361419

Moxifloxacin for tuberculosis.

Carl Mendel, Martin Springsklee.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22361419     DOI： 10.1016/S1473-3099(11)70351-6

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  2 in total

1.  A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection.

Authors:  John Gar Yan Chan; Anneliese S Tyne; Angel Pang; Hak-Kim Chan; Paul M Young; Warwick J Britton; Colin C Duke; Daniela Traini
Journal:  Pharm Res       Date:  2013-11-16       Impact factor: 4.200

2.  Moxifloxacin resistance in the F15/LAM4/KZN extensively drug-resistant strain of Mycobacterium tuberculosis.

Authors:  Navisha Dookie; A Willem Sturm; Prashini Moodley
Journal:  Infect Drug Resist       Date:  2014-08-19       Impact factor: 4.003
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.